+49-6221-8936-157
contact [at] therapyselect [dot] dePCDx™ is one of the first tumor profiling service that combines comprehensive laboratory testing with clinical research/evidence on molecular-based biomarkers to aid physicians as they evaluate potential drug or clinical trial options. A PCDx™ Report is generated for each patient and may help your doctor personalize cancer therapies specific to your cancer/tumor.
Paradigm Diagnostics is a bioscience company focused on personalized medicine. Paradigm Diagnostics offers comprehensive molecular-based biomarker analysis. Paradigm Diagnostics correlates molecular data from a patient’s tumor with drug targets derived from clinical cancer studies. Using a variety of advanced technologies, molecular information for approximately 83 FDA-approved drug associations are provided to your physician to personalize treatment for you.
The results of these tests reveal your tumor’s specific cancer molecular-based biomarkers, or targets, which are then matched to treatments having potential clinical benefit or lack of benefit for your tumor. Paradigm Diagnostics matches the molecule-based biomarkers to the treatments using an extensive review of the strongest and most relevant cancer related clinical and scientific studies. This information may be used by your physician to personalize your treatment, which may lead to better treatment response.
You have been diagnosed with a solid tumor cancer and your physician is seeking additional treatment information when:
- your cancer has metastasized or recurred;
- you are facing aggressive or rare cancer;
- your physician is navigating multiple treatment options; or
- you have run out of standard treatment options to fight your cancer.
No, a ‘diagnostic’ test determines whether someone may have a particular disease or medical condition. The Report is designed to help your physician identify which of the available therapies may have the best chance to work against your cancer and which to potentially avoid.
The PCDx™ Report is a tool provided to your physician to ensure they have the most advanced data when evaluating how to attack your tumor the best. Your physician will determine your treatment plan which will be based on many factors that may include the Report, availability of cancer therapeutics, medical history and other clinical factors.
The Report may include molecular-based biomarkers in clinical trials. This service identifies clinical trials that are currently enrolling patients based on the unique biomarkers in your tumor. Your physician will determine if any of these trials may be right for you.
PCDx™ is performed on tissue that is routinely obtained during the surgical removal of your tumor, or from a sample collected during a biopsy. As your tumor’s biomarkers may change over time and with treatment, your physician may wish to obtain a more recent sample of your tumor.
If you or your physician prefers, TherapySelect can organize the entire logistics. The archived specimen will be picked up by TherapySelect at the pathology or it can be sent directly to TherapySelect. Fresh samples can be shipped with a special transport kit to us. The kit will be provided before surgery. As soon as we have the tumor sample we will process the sample - if needed - and forward it afterwards to Paradigms' laboratory.
PCDx™ is performed at Paradigms' laboratory in Phoenix, Arizona. This state-of-the-art lab is CLIA-certified and is staffed by MDs, PhDs and licensed technologists.
The process takes approximately 4-5 business days. The PCDx™ Report will be delivered directly to you and your physician for review.
The results will be sent as a writen report to you and your physican as a letter and if requested as fax or as secured email. In addition your physician can access the report online.
For ordering the PCDx™ in Germany we need the requisistion form, which needs to be filled out by the physician, and the patient information and order form, which needs to be signed by the patient. Both documents can be sent to us via fax or mail.
In our services the following offerings are included:
- the shipping costs of the tumor sample,
- performing the requested analyses,
- the interpretation of the data and
- the final report
The report will be provided to you and the physician. The PCDx™ Report also contains information about possible beneficial clinical trials. The oncologist has the chance to discuss the case with Paradigm's oncologist(s).
If you have further questions you can contact TherapySelect Dr. Frank Kischkel. We try to answer them and help you as much as possible.
In Germany Paradigm Diagnostics is represented by
TherapySelect Dr. Frank Kischkel
Carl-Bosch-Str. 4
69115 Heidelberg
Telefon: 06221-8936-157
Fax: 06221-8936-158
Email: paradigm@therapyselect.de
Web: www.therapyselect.de
